Caplin Point Laboratories · NSE: CAPLIPOINT · BSE: 524742
Q4 FY21 results · Jan–Mar 2021
Caplin Point Laboratories reported revenue from operations of ₹278.71 crore and net profit of ₹67.92 crore for Q4 FY21 (Jan–Mar 2021), on a consolidated basis.
| Item | Q4 FY21 | Q4 FY20 | YoY | Q3 FY21 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 278.71 | — | — | — | — |
| Other income | 9.46 | — | — | — | — |
| Total income | 288.17 | — | — | — | — |
| Profit before tax | 84.97 | — | — | — | — |
| Net profit for the period | 67.92 | — | — | — | — |
| Attributable to shareholders of the company | 66.37 | — | — | — | — |
| EPS, basic (₹) | 8.78 | — | — | — | — |
| Net margin (%) | 24.4 | — | — |
| Item | Q4 FY21 | Q4 FY20 | YoY | Q3 FY21 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 122.88 | 100.12 | +22.7% | 123.16 | −0.2% |
| Other income | 7.36 | 33.01 | −77.7% | 3.98 | +84.9% |
| Total income | 130.24 | 133.14 | −2.2% | 127.14 | +2.4% |
| Profit before tax | 44.64 | 65.81 | −32.2% | 55.31 | −19.3% |
| Net profit for the period | 31.49 | 50.15 | −37.2% | 41.48 | −24.1% |
| EPS, basic (₹) | 4.16 | 6.63 | −37.3% | 5.48 | −24.1% |
| Net margin (%) | 25.6 | 50.1 | 33.7 |
Consolidated
- Filed with BSE
- 07 May 2021, 14:28 IST
- Board meeting
- 06 May 2021
- Period
- 01 Jan 2021 to 31 Mar 2021
- Review status
- Audited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 07 May 2021, 14:28 IST
- Board meeting
- 06 May 2021
- Period
- 01 Jan 2021 to 31 Mar 2021
- Review status
- Audited
- Source
- XBRL filing on BSE